Integra LifeSciences Holdings Stock
Integra LifeSciences Holdings Corporation
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Stuart Essig
- Employees
- 4,427
- Market cap
- $1 B
- IPO
- 16/08/1995
Integra LifeSciences Holdings Corporation (IART) is a US-based company in the healthcare / medical - devices industry, specializing in the manufacture and global distribution of surgical implants and instruments. Operating since 1989, the company divides its portfolio into two core business segments: Codman Specialty…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Integra LifeSciences Holdings stock: price history
1D
-2.4%
1W
-1.7%
1M
-17.7%
6M
+18.6%
YTD
+6.4%
1Y
-9.6%
2Y
-33.3%
5Y
-80.5%
10Y
-67.6%
Next earnings date
Next earnings date
21/10/2026 (in 4 days)
Volatility around earnings
~165% stronger price swings than usual
Integra LifeSciences Holdings stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
Integra LifeSciences Holding Corporation is a medical device company specializing in the development and global distribution of surgical implants and instruments. The business model is divided into two main segments: Codman Specialty Surgical, which offers neurosurgical products such as monitoring systems and stabilization aids, and Tissue Technologies, which provides innovative solutions for tissue and wound healing. Sales are conducted through specialized distribution teams directly to a broad base of healthcare facilities, including hospitals, surgical centers, and specialty practices worldwide. The portfolio comprises over 40,000 different instrument designs for various medical applications.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Integra LifeSciences Holdings
Analyst assessment of Integra LifeSciences Holdings
PRICE TARGET LOW
US$15.00
CONSENSUS
US$19.40
MEDIAN
US$19.00
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
11
BUY
12
HOLD
4
SELL
0
STRONG SELL
27
TOTAL · Hold
As of: 14/10/2026
Integra LifeSciences Holdings stock metrics
P/E
-143.28
P/B
0.98
EV/EBITDA
11.43
RETURN ON EQUITY
0.4%
NET MARGIN
1.1%
DEBT/EQUITY
1.94
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
75.4%
FLOAT SHARES
58,651,358
AVG. DAILY VOLUME (30D)
1,090,143
Insider transactions (SEC)
Veillon-Berteloot Chantal
Mosebrook Jeffrey
Knight Lea Daniels
BRADLEY KEITH
HILL BARBARA B
Attention
Price since yesterday: -2.4%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Smart Money
Register for free
Register now to see which funds are invested
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Comparable stocks
Frequently asked questions about Integra LifeSciences Holdings stock
What does Integra LifeSciences Holdings do?
Integra LifeSciences Holdings Corporation is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Stuart Essig, the company employs around 4,427 people.
The IPO was on 16/08/1995; the stock trades on NASDAQ under the ticker IART.
What do analysts say about Integra LifeSciences Holdings stock?
27 analysts rate the stock, the consensus is Hold (as of 14/10/2026).
The average price target is US$19.40, ranging from US$15.00 to US$25.00, with a median of US$19.00.
This is an external assessment, not a statement by Market Jury.
When does Integra LifeSciences Holdings report next?
The next earnings date is 21/10/2026.
Around past earnings, price swings were roughly 165% stronger than usual.
Does Integra LifeSciences Holdings pay a dividend?
No, Integra LifeSciences Holdings currently does not pay a dividend.
Which stocks are comparable to Integra LifeSciences Holdings?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Integra LifeSciences Holdings stock analyzed?
Clicking "Analyze stock" lets five strategies assess Integra LifeSciences Holdings against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.